S-Nitrosoalbumin (SNO-Alb) has been shown to be an efficacious cytoprotective molecule in acute lung injury as well as ischemia/reperfusion injury in heart and skeletal muscle. Nonetheless, limited information is available on the cellular mechanism of such protection. Accordingly, we investigated the protective effects of SNO-Alb (and its denitrosated congener, reduced albumin (SH-Alb)) on tert-butyl hydroperoxide (tBH)-mediated cytotoxicity in cultured rat pulmonary microvascular endothelial cells (RPMEC) as well as hydrogen sulfide (H 2 S)-mediated cytotoxicity in rat pulmonary artery smooth muscle cells (RPASMC). We noted that tBH caused a concentrationdependent necrosis in RPMEC and pretreatment of RPMEC with SNO-Alb dosedependently decreased the sensitivity of these cells to tBH. A component of SNO-Alb cytoprotection was sensitive to L-NAME and was associated with activation of eNOS; phenomena that could be reproduced with pretreatment with SH-Alb. Exogenous H 2 S caused concentration-dependent apoptosis in RPASMC due to activation of ERK 1/2 and p38 as well as down-regulation of Bcl-2. Pretreatment with SNO-Alb reduced H 2 Smediated apoptosis in a concentration-dependent manner that was associated with SNOAlb mediated inhibition of activation of ERK 1/2 and p38. Pretreatment with SNO-Alb reduced toxicity of 1 mM NaHS in an L-NAME sensitive fashion in RPASMC that expressed gp60, nNOS and were capable of transporting fluorescently labeled SH-Alb.
ABSTRACT:
S-Nitrosoalbumin (SNO-Alb) has been shown to be an efficacious cytoprotective molecule in acute lung injury as well as ischemia/reperfusion injury in heart and skeletal muscle. Nonetheless, limited information is available on the cellular mechanism of such protection. Accordingly, we investigated the protective effects of SNO-Alb (and its denitrosated congener, reduced albumin (SH-Alb)) on tert-butyl hydroperoxide (tBH)-mediated cytotoxicity in cultured rat pulmonary microvascular endothelial cells (RPMEC) as well as hydrogen sulfide (H 2 S)-mediated cytotoxicity in rat pulmonary artery smooth muscle cells (RPASMC). We noted that tBH caused a concentrationdependent necrosis in RPMEC and pretreatment of RPMEC with SNO-Alb dosedependently decreased the sensitivity of these cells to tBH. A component of SNO-Alb cytoprotection was sensitive to L-NAME and was associated with activation of eNOS; phenomena that could be reproduced with pretreatment with SH-Alb. Exogenous H 2 S caused concentration-dependent apoptosis in RPASMC due to activation of ERK 1/2 and p38 as well as down-regulation of Bcl-2. Pretreatment with SNO-Alb reduced H 2 Smediated apoptosis in a concentration-dependent manner that was associated with SNOAlb mediated inhibition of activation of ERK 1/2 and p38. Pretreatment with SNO-Alb reduced toxicity of 1 mM NaHS in an L-NAME sensitive fashion in RPASMC that expressed gp60, nNOS and were capable of transporting fluorescently labeled SH-Alb.
Therefore, SNO-Alb is cytoprotective against models of oxidant induced necrosis (tBH) and inhibitors of cellular respiration and apoptosis (H 2 S) in both pulmonary endothelium and smooth muscle, respectively, and a component of such protection can be attributed to a SH-Alb mediated activation of constituitive NOS.
Keywords: S-nitrosoalbumin; reduced albumin; pulmonary endothelium; pulmonary smooth muscle; tert-butyl hydroperoxide; Hydrogen sulfide; necrosis; apoptosis; nitric oxide synthase; MAPK INTRODUCTION S-nitrosoalbumin (SNO-Alb) was recently shown to be effective in mitigating LPSinduced acute lung injury (ALI) in intact rats (12) and hypoxia-regenerated ALI in sickle cell disease model in mice (6) . Pretreatment of intact pigs with polynitrosated bovine albumin decreased LPS induced cardiopulmonary dysfunction (9). These reports were a logical extension of initial observations demonstrating a cytoprotective role of SNO-Alb in ischemia-reperfusion (I/R) injury of skeletal muscle (11) and heart (20) and hemorrhagic shock induced changes in liver (1).
Although the above studies provide a compelling preclinical interest in the uniqueness and advantages of SNO-Alb over other NO donors including low molecular weight Snitrosothiols and authentic NO, itself, in sepsis or shock, most of the efforts: a) were directed towards cytoprotection of microcirculation in the context of platelet aggregation or leukocyte-endothelial cell adhesion (1); b) generally discounted a contribution of reduced albumin (12); and c) overall formed the basis of new questions with respect to cellular mechanisms by which SNO-Alb was protective. In the current study, we examined the potential of SNO-Alb to affect necrotic as well as apoptotic pathways in both pulmonary endothelium and smooth muscle. We previously reported (31) that SNOAlb was indeed capable of transnitrosating targets in intact pulmonary endothelium and this effect was sensitive to inhibition of cell surface protein disulfide isomerase (csPDI) as originally shown by Ramachandran et al (19) . This raises the possibility that (reduced) albumin formed by denitrosation of SNO-Alb can contribute to the overall effect under study (e.g. cytoprotection) perhaps secondary to activation of gp60 in pulmonary endothelial cells (25) accounting for albumin transcytosis as well as activation of endothelial nitric oxide synthase (eNOS, NOSIII) (16) . We now show that pulmonary smooth muscle cells also express gp60 (and neuronal nitric oxide synthase, nNOS) and are also capable of transporting albumin. The L-NAME sensitive component (secondary to activation of NOS via SH-Alb) of SNO-Alb in pulmonary smooth muscle and endothelium underscores the contributory role of albumin mediated NOS activation in such cytoprotection. Insight into potential cytoprotective mechanisms is provided in H 2 Smediated apoptosis of pulmonary smooth muscle where SNO-Alb interferes with ERK1/2 and p38 activation. ), caspase-3, ERK 1/2, P-ERK 1/2, p38 and P-p38 were purchased from Cell Signal Technology (Beverly, MA, USA).
EXPERIMENTAL PROCEDURES

Materials
eNOS, nNOS, Bcl-2, HRP-conjugated anti-rabbit and anti-mouse antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibody to gp60 was a kind gift from Dr. Asrar Malik (University Illiniois at Chicago). PD 98059 and SB 203580 were purchased from Calbiochem (San Diego, CA, USA). NaHS solution was freshly prepared on the day of every experiment by mixing the stock solutions of sodium sulfide and hydrochloric acid.
Cell Culture. Rat pulmonary microvascular endothelial cells (RPMEC) were cultured in MCDB-131 complete medium (VEC Technologies, Rensselaer, NY, USA). Rat pulmonary artery smooth muscle cells (RPASMC) were isolated as previously described (18) and grown in DMEM (low glucose) with 10% FBS, 1000 U/ml penicillin and 1 mg/ml streptomycin. All cells were incubated at 37°C in a humidified atmosphere of air and 5% CO 2 .
Preparation of S-Nitrosoalbumin. Human albumin (HSA) (50 mg/ml) was initially treated for 45 to 60 minutes at room temperature in the dark with 1 mM dithiothreitol (DTT) in PBS supplemented with 640 μM diethylenetriaminepentaacetic acid (DTPA) to reduce the cysteine-34 thiol group (HSA-SH). After extensive washing with Chelextreated PBS (Sigma, pH 7.4), the mixture was centrifuged (14,000 g, 25 minutes, 4°C) and fractionated with 30,000 Da cut-off filter (Millipore, MA, USA). Albumin ) by using the Ellman's reagent. Nitrosylated human albumin (SNO-Alb) was prepared using transnitrosylation reaction and S-nitroso-glutathione (GSNO) as a donor. GSNO was prepared by the reaction of acidified NaNO 2 with glutathione. Briefly, 100 mM glutathione was mixed with 100 mM NaNO 2 in 200 mM HCl at room temperature. pH was adjusted to 7.4 with NaOH, and the solution was used for S-transnitrosylation of HSA-SH. For S-transnitrosylation, reduced human serum albumin (SH-Alb) was mixed with 50 times excess of GSNO and the solution was incubated in the dark for 20 minutes at room temperature. To prevent S-glutathiolation of SH-Alb, the reaction was stopped with N-ethylmaleimide (4:1, mol NEM to mol HSA-SH), and the samples were extensively washed as described above to remove low-molecular-weight components.
The resultant SNO-Alb preparation was checked for the level of residual SH-Alb as well as SNO-Alb using Ellman's reagent and 4,5-diaminofluorescein (DAF-2) assays, respectively. The molar ratio of reduced sulfhydryls to total albumin was < 0.01 and the molar ratio of SNO-Alb to total albumin was ~ 0.55 (2) .
Cell viability assay. Cell viability was determined using alamarBlue LDH release assay and caspase activity assay. LDH release was measured using CytoTox-ONE homogeneous membrane integrity assay (Promega, WI, USA). Caspase activity was determined using Caspase-Glo Immunoblot. Cells were washed three times with ice-cold PBS, and then lysed on ice in SDS sample buffer (62.5 mM Tris-HCl, pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% w/v bromophenol blue). The extracts were sonicated briefly, boiled for 5 min, then centrifuged at 14,000 rpm for 5 min. Equivalent amounts of protein were separated by electrophoresis using 10% SDS-PAGE gels. The proteins were then transferred to PVDF membrane (Invitrogen, CA, USA) and blocked with PBS containing 5% nonfat milk for 1 hour at RT. The membrane were incubated with primary antibody overnight at 4°C, HRP-conjugated secondary antibody was used for visualization by chemiluminescence using ECL reagent (Perkin-Elmer Life Science, MA, USA). Blots were stripped with stripping buffer (Pierce, IL, USA) and reprobed. Densitometric analysis was performed using Image J software from the NIH.
Endothelial NOS Phosphorylation. RPMEC were grown on 6-well plates to 90% confluence, subsequently serum deprived for 2 hours in serum-free MCDB-131 medium, and then treated with SNO-Alb (20 μM), SH-Alb (20 μM) and anti-gp60 polyclonal antibody (10 μg/ml) in serum-free HBSS (Invitrogen, CA, USA) for 30 minutes. Cell lysates were collected for immunoblot analysis.
Uptake of reduced albumin. RPMEC and RPASMC were plated into Lab-Tek II 4-well chamber slides (Nalge Nunc, IL, USA) and grown until 90% confluent. After washing with HBSS, cells were incubated with HBSS-BSA (5 mg/ml) at 37ºC for 10 minutes and then exposed to 50 μg/ml of Alexa 488-BSA (Invitrogen, CA, USA) for 20 minutes at 37ºC. Cells were fixed with 4% paraformaldehyde and stained with DAPI (Invitrogen, CA, USA) to reveal cell nuclei and then slides were peeled off and sealed with Fluoromount-G (Southern Biotechnology Associates, AL, USA) under coverslips.
Data analysis.
Statistical analyses were performed with one-way analysis of variance (ANOVA) within groups followed by pairwise multiple comparison procedure (HolmSidak method). Data were presented as means ± SD. Statistical significance was defined as P < 0.05.
RESULTS
tBH-induced necrosis rather than apoptosis in RPMEC
tert-butyl hydroperoxide (tBH) caused a concentration dependent toxicity in RPMEC ( Figure 1A ) as determined by alamarBlue®. There was no apparent toxicity of tBH (0-100 µM) in RPASMC (data not shown). Toxicity to tBH in RPMEC was likely due to necrosis as there was: a) a concentration dependent (Fig 1B) increase in propidium iodide positive cells by FACS ( Figure 1C ); b) a concentration dependent increase in LDH release that approached maximum release from standard lysis protocol ( Figure 1D ); and c) no change in caspase 3/7 activity in an otherwise staurosporine sensitive RPMEC ( Figure 1E ) or immunostaining of M30 (data not shown). Accordingly, tBH was associated with necrotic but not apoptotic cell death in RPMEC.
Effect of SNO-Alb on tBH-induced cytotoxicity in RPMEC
We then examined the effect of 1 hour pretreatment with SNO-Alb (0-20 μM) on tBH We then evaluated the contributing role of endogenous NO production in the cytoprotective effect of SNO-Alb and noted that a statistically significant component of SNO-Alb cytoprotection was L-NAME sensitive in RPMEC ( Figure 2B ). A likely explanation is that denitrosation of SNO-Alb occurred and that the reduced form (SHAlb) activated eNOS (16) . Such denitrosation was not likely to have occurred in the extracellular space in a readily detectable fashion under the conditions of our experiment as there was no increase in nitrite in the medium of SNO-Alb conditioned RPMEC ( Figure 2C ). We noted, however, that SH-Alb, itself, was cytoprotective in an L-NAME sensitive fashion in RPMEC ( Figure 2B ) while rat IgG had no protective effect on tBHinduced cytotoxicity. We then noted that RPMEC expressed gp60 and eNOS ( Figure 3A) and were capable of transporting fluorescent labeled (Alexa 488) reduced albumin ( Figure 3B ). Furthermore, exposure of RPMEC to SNO-Alb or SH-Alb mimicked activation of eNOS observed via gp60 activation by gp60 antibody ( Figure 3C ).
H 2 S-induced apoptosis rather than necrosis in RPASMC
In screening the toxicity of other conditions in RPASMC, we noted that these cells were sensitive to NaHS whereas RPMEC were resistant over a comparable large concentration range ( Figure 4A ). In investigating the pathway of cell death after exposing RPASMC to 0.5 mM NaHS, we noted activation of caspase 3 ( Figure 4D ) at 4 hours without significant release of LDH ( Figure 4B ) as well as early and late apoptosis detection in flow cytometry ( Figure 4C ). Accordingly, H 2 S was associated with apoptotic but not necrotic cell death in RPASMC.
Effect of SNO-Alb on H 2 S-induced cytotoxicity in RPASMC
Pretreatment of RPASMC with 20 µM SNO-Alb, that did not affect cell viability in itself, significantly reduced the toxicity of NaHS as determined by alamarBlue ® ( Figure   5A ). We confirmed this effect using trypan blue exclusion by showing that 0.5 mM NaHS reduced cell viability to 56% of control and this toxicity was completely inhibited by pretreatment with 20 µM SNO-Alb (data not shown). In further studies using alamarBlue ® and a high dose (1.0 mM) NaHS, we noted that the protective effect of SNO-Alb (20 µM) was sensitive to L-NAME (1 mM) and could be mimicked by 20 µM SH-Alb and this effect was also sensitive to L-NAME ( Figure 5B ). Although lower doses of NaHS resulted in toxicity that was sensitive to SNO-Alb, there was no significant L-NAME sensitive component. RPASMC, like endothelial cells, transported Alexa 488 labeled reduced albumin ( Figure 5C ). In addition ( Figure 5D ), they expressed gp60 and nNOS (but not eNOS) that may account for the L-NAME sensitive component of SNOAlb and SH-Alb cytoprotection. Furthermore, early (by two hours) in the course of NaHS induced apoptosis, we noted activation of ERK 1/2 ( Figure 6A ) and a decrease in Bcl-2 expression ( Figure 6B ). We then showed that NaHS activated not only ERK 1/2 ( Figure   6C ) but also p38 ( Figure 6D ) and that phosphorylation of both these kinases was (19) and/or inside (19, 31) the cell. We report that pulmonary smooth muscle cells, like pulmonary endothelium ( Figure 3A) , express gp60 ( Figure 5D ) and can transport SH-Alb ( Figure 5C ). Such transport appears coupled to activation of nitric oxide synthase in RPMEC and RPASMC as the protective effect of SNO-Alb was sensitive to L-NAME and mimicked by SH-Alb ( Figure 2B and Figure 5B , respectively). Although the mechanism underlying protection against tBH in pulmonary endothelium remains unclear, it is noteworthy that SNO-Alb appears to protect RPASMC from toxicity (apoptosis) of H 2 S by inhibition of activation of MAP kinases (ERK1/2 and p38; Figure   6 ).
Several preclinical studies support the therapeutic potential and uniqueness of SNOAlb to protect and mitigate against microvascular injury including experimental models of acute lung injury (ALI). The original work by Hallstrom and colleagues (11) demonstrated that SNO-Alb could preserve endothelial cell integrity in heart and skeletal muscle in ischemia/reperfusion injury in intact animals and was not associated with a hypotensive effect. Subsequently a number of investigators have revealed a protective role for SNO-Alb in intact animals in experimental models of ALI including hypoxiareoxygenation of sickle cell mice (6) and pretreatment of LPS-exposed pigs (9) and posttreatment of LPS-exposed rats (12). A common experience in this collective body of work is that SNO-Alb, in contrast to other NO donors including low molecular weight thiols, has minimal untoward effects such as systemic hypotension. SNO-Alb enhances microvascular function in these models by inhibiting platelet aggregation or neutrophil accumulation. An added feature in some studies is the contribution of albumin in the mixture (6) (see below) and an important therapeutic feature that mitigation (delivering SNO-Alb after onset of LPS exposure) is possible (12). SNO-Alb is more stable than other sources of NO and indeed under various conditions is considered as a major endogenous plasma reservoir of circulating NO (23, 26) .
SNO-Alb and tBH toxicity
Exposure of RPMEC to tBH, like our previous report with cultured sheep pulmonary artery endothelial cells (24) , resulted in necrosis without apoptosis (Figure 1 Although we have not identified specific nitrosated targets in rat pulmonary endothelium, we previously reported the capabilities of SNO-Alb to nitrosate a surrogate fluorescence resonance energy transfer reporter for transnitrosation in rat pulmonary endothelial cells (31) suggesting that such biochemistry is apparent in SNO-Alb treated RPMEC.
Maniatis et al (16) described a unique phenomenon in which binding to gp60 (albumin receptor) in cultured pulmonary endothelial cells results in activation of eNOS secondary to caveolae mediated endocytosis. In our study, it is noteworthy that SH-Alb produced partial protection of RPMEC to tBH in an L-NAME sensitive fashion and that SNO-Alb protection partially involved an L-NAME sensitive pathway ( Figure 2B ). The likely role of endogenous NO (e.g. eNOS derived NO) in cytoprotective effects of SNO-Alb and reduced albumin is also apparent in the ability of SNO-Alb, SH-Alb and gp60 to activate eNOS ( Figure 3C ).
SNO-Alb and Hydrogen Sulfide Toxicity
Hydrogen sulfide is synthesized in a number of mammalian tissues from L-cysteine by the action of cysathionine-β-synthase or cysathionine-γ-lyase and has emerged as an important newly recognized signal transduction molecule joining nitric oxide and carbon monoxide as so-called gaseous transmitters (27, 28 ). The physiological effects of H 2 S are oftentimes confounding (anti-vs. pro-inflammatory; vasodilator vs. vasoconstrictor) and such diametrically opposed observations may be secondary to the concentration of H 2 S (27). At a somewhat supraphysiological level, inhaled H 2 S has attracted extraordinary attention by virtue of its ability to induce suspended animation (4) . Investigations into its physiological or therapeutic role are always influenced and balanced by the long history of toxicity of H 2 S (including its telltale odor of rotten eggs and its well known ability to inhibit cytochrome c oxidase (14) ). As such, most information of toxicity of H 2 S in vascular tissue is derived from systemic smooth muscle (30) and little is known regarding toxicity of H 2 S in pulmonary vascular tissue or the ability of NO donors to affect H 2 S toxicity in the lung.
In the current study, we utilized NaHS as a source of exogenous H 2 S. NaHS solution was freshly prepared on the day of every experiment by mixing the stock solution of sodium sulfide and hydrochloric acid. In normal physiological solution, one-third of NaHS exists as H 2 S, and the other two-third exists as HS - (3) . Although this approach is common in cell biology and greatly simplifies use of H 2 S, as with any chemical donor, it is only a surrogate for authentic H 2 S. Nonetheless, the potential concentrations used in the current study most likely exceeded physiological concentrations (45-300 µM) of H 2 S in plasma (32) .
Our studies extend previous information on pro-apoptotic effects of H 2 S in systemic vascular smooth muscle (7, 30). We report that exogenous H 2 S released from NaHS had a pro-apoptotic effect on RPASMC (Figure 4 ) but endothelial cells were resistant to comparable concentration range of H 2 S ( Figure 4A ). H 2 S induced ERK 1/2 and p38 ( Figure 6 ) phosphorylation accompanied by down-regulation of Bcl-2 and caspase-3 activation ( Figure 4D ). The critical role of MAPK activation and H 2 S induced apoptosis was apparent in the sensitivity of this process ( Figure 6E ) to PD 98059 (ERK1/2 inhibitor) and SB 203580 (p38 inhibitor). The cytoprotective effect of SNO-Alb against NaHS reinforced this concept and suggested a possible mechanism in which SNO-Alb protects RPASMC from NaHS since SNO-Alb inhibited NaHS induced activation of ERK1/2 and p38. Nonetheless, the precise molecular mechanism in which SNO-Alb affects these complex kinase pathways is unclear. In addition, the protective effect of SNO-Alb was sensitive to L-NAME and the effect could be mimicked (at high doses of NaHS) with SH-Alb ( Figure 5B ) which in turn was sensitive to L-NAME. Apparently, activation of nNOS secondary to binding and uptake of SH-Alb ( Figure 5C (19) ; and c) plasma membrane components (e.g. ion channels, receptors, etc) are not likely to be trans-Snitrosated by bulky RSNOs such as SNO-Alb. In contrast, as we have shown (5), the first site of action of low molecular weight RSNO, especially unhindered compounds, is likely to be the thiol rich plasma membrane of cells. It could be further speculated that, in cells, SNO-Alb will participate in a complex equilibrium with glutathione, nitroso-glutathione (GSNO) and thioredoxin type 1, which is likely to be shifted in favor of GSNO (21, 22) .
In conclusion, SNO-Alb appears to be a unique NO donor in that it is relatively stable and its secondary reactions are primarily transnitrosation perhaps limiting more oxidizing species of secondary nitrogen monoxides common to other NO donors including authentic NO itself. Although it is unclear why RPMEC were resistant to NaHS (in comparison to RPASMC), it is noteworthy that SNO-Alb reduced the sensitivity of pulmonary vascular cells to either necrosis (tBH in RPMEC) or apoptosis (NaHS in RPASMC). Details of the latter protection are consistent with SNO-Alb interfering with Three subcultures of RPASMC were tested for gp60, nNOS and eNOS expression by using western blotting. Data are presented as Means ± SD, three independent experiments were performed. * P < 0.05 compared with control, # P < 0.05 compared with NaHS treatment, † P < 0.05 compared with NaHS and SNO-Alb treatment, ‡ P < 0.05 compared with NaHS and SH-Alb treatment. 
